Under EU MDR (Regulation (EU) 2017/745), post-market surveillance (PMS) data isn’t a compliance afterthought. It’s the evidence base notified bodies, competent authorities, and increasingly payers will use to decide whether your wound care product stays on the market and what claims it can carry. For cellular, acellular, and matrix-like products (CAMPs, also called cellular and/or tissue-based products, or CTPs, in the US), advanced dressings, and negative pressure wound therapy (NPWT) systems, the bar for what counts as adequate PMS and post-market clinical follow-up (PMCF) data has risen steadily since MDR became fully applicable on May 26, 2021, and wound care manufacturers continue to get tripped up on the same gaps. This article breaks down what qualifies as post-market surveillance data under EU MDR, where those gaps typically show up, and how structured real-world utilization data fits into a PMCF file that can withstand notified body scrutiny.
What Counts as Post-Market Surveillance Data Under EU MDR?
EU MDR treats post-market surveillance as a system, not a single deliverable. Article 83 establishes PMS as the umbrella obligation: manufacturers must proactively collect and evaluate data on their device’s performance and safety throughout its lifecycle, feeding that data back into the risk management file and clinical evaluation. Post-market clinical follow-up, required under Article 61 and defined and detailed in Annex XIV Part B, is the proactive subset of PMS focused specifically on generating clinical data, real-world performance data, identification of previously unknown risks, and confirmation of benefit-risk determinations under actual conditions of use. For Class IIa, IIb, and III devices, the periodic safety update report (PSUR), required under Article 86, is the output document that summarizes PMS findings, including PMCF results, on a schedule tied to device risk class; Class I devices file a PMS report under Article 85 instead. The MDCG’s PSUR guidance, MDCG 2022-21, sets out the expected structure.
Notified bodies generally expect manufacturers to structure PMCF plans and evaluation reports around the MDCG templates: MDCG 2020-7 for the PMCF plan and MDCG 2020-8 for the PMCF evaluation report. These remain the reference documents most notified bodies cite as of this writing. The broader PMS system is now also addressed by MDCG 2025-10, published in December 2025. MDCG guidance is revised and renumbered periodically, so manufacturers should confirm current status and any superseding documents on the European Commission’s MDCG endorsed documents page before finalizing a submission.
A mistake seen across wound care files: treating complaint handling and vigilance reporting as sufficient PMCF evidence. Complaint and vigilance data are reactive: they capture what goes wrong, not how a product performs across its intended population. MDCG 2025-10 makes the point directly, stating that complaint handling and vigilance alone do not constitute an adequate PMS system. For higher-risk wound products, that is, most CAMPs/CTPs and combination NPWT-dressing systems, notified bodies expect systematic, planned data collection designed to answer specific clinical questions about performance, not just a passive log of adverse events. A PMCF plan built entirely on existing complaint databases is one of the more predictable deficiency findings during technical file review.
Why Do Wound Care Products Face Heightened PMS Scrutiny?
Many advanced wound care products sit in higher MDR risk classifications, or in classification zones that are genuinely borderline between medical device and other regulatory frameworks. Under MDR Annex VIII, dressings intended for wounds that breach the dermis and heal only by secondary intent fall under Rule 4 (Class IIb), and devices incorporating non-viable animal tissue fall under Rule 18 (Class III), as explained in the MDCG classification guidance, MDCG 2021-24. A product’s EU MDR classification does not automatically mirror its US regulatory pathway. A skin substitute regulated as a device in one market may fall under a different framework elsewhere; human tissue-based products, for example, are largely handled in the EU under the Substances of Human Origin (SoHO) Regulation (EU) 2024/1938 rather than MDR. Biologic-versus-device distinctions handled in the US through FDA’s Section 351 biologics pathway, the Section 361 HCT/P framework (21 CFR Part 1271), or device pathways don’t map cleanly onto MDR’s classification rules. Manufacturers with products marketed on both sides of the Atlantic need to verify EU classification independently for each SKU rather than assuming continuity with the US regulatory determination.
Chronic wound populations compound the scrutiny. Patients with diabetic foot ulcers (DFUs), venous leg ulcers (VLUs), and pressure ulcers are clinically heterogeneous: variable vascular status, glycemic control, nutritional status, and comorbidity burden mean that outcomes from a single-site study or a short follow-up window generalize poorly. US Wound Registry research on the Wound Healing Index showed how strongly these patient- and wound-level factors predict healing. Regulators and notified bodies know this, which is part of why they lean more heavily on broader real-world PMS datasets for wound care than they might for more homogeneous device categories. A twelve-week randomized controlled trial (RCT) in a controlled population tells a notified body less about real-world healing performance in a mixed skilled nursing facility (SNF) or home-health population than it might for other device types; Carter, Fife, et al. found that typical wound care RCT eligibility criteria would exclude most patients seen in routine wound care.
Notified bodies are also increasingly asking for comparative effectiveness data rather than safety data alone, particularly when marketing materials or clinical claims imply a product outperforms standard-of-care dressings or competing CAMPs/CTPs. A safety-only PMCF file no longer satisfies review when the manufacturer’s own commercial claims invoke comparative superiority. MDR Article 7 prohibits labeling and promotional claims that ascribe performance a device does not have. If your labeling or sales collateral claims faster time-to-closure than an alternative product class, your PMCF evidence needs to support that specific comparison, not just confirm the device doesn’t harm patients. Head-to-head wound care product rankings built on real-world outcomes are one way to test those claims before a reviewer does.
What Real-World Data Sources Satisfy EU MDR’s Evidence Expectations?
Acceptable PMS/PMCF data sources generally fall into four categories: clinical registries, systematic literature surveillance, structured user and patient feedback mechanisms, and real-world data platforms that track utilization across care settings. MDCG 2020-7 lists registries, literature review, and surveys among recognized PMCF methods. None of these substitutes for the others; a defensible PMCF file typically triangulates across more than one source type. Manufacturers without an existing registry can build a product-specific wound care registry designed around their PMCF questions.
Utilization-pattern data is often the most underused source in wound care PMCF files. Understanding how a product is actually deployed, across hospital-based wound centers, skilled nursing facilities, and home visits, tells you something a controlled trial population cannot: whether real-world usage matches labeling, whether outcomes hold up outside the original trial population, and whether the product is being substituted for or against specific competitor categories. This is the type of dataset that platforms like Intellicure Analytics’ Wound Care Industry Dashboard and Comparative Effectiveness Studies are built to supply, tracking product utilization and outcome trends across care settings at a scale most single-manufacturer PMCF studies cannot reach on their own. That data is captured as structured, discrete fields at the point of care through the IntellicureEHR wound care documentation platform.
A caution worth stating plainly: most large-scale real-world wound care datasets, including claims and EMR-derived data, originate in the US healthcare system. That data can be genuinely useful for signal detection and hypothesis generation, but manufacturers citing US-derived real-world data in an EU PMCF report need to document data provenance explicitly and assess transferability to European care pathways, reimbursement structures, and patient populations before leaning on it as primary evidence. A notified body reviewer will ask where the data came from and whether the population and care setting resemble the EU context the clinical evaluation report (CER) is meant to address. Undocumented provenance, or an unexamined assumption that US utilization patterns transfer directly to EU practice, is an easy way to undermine an otherwise solid PMCF submission.
How Do You Meet EU MDR PMCF Requirements for Wound Care Products?
The PMCF cycle under MDR is iterative by design, not a one-time study. It starts with a PMCF plan tied directly to the risk management file and CER, identifying specific questions the plan needs to answer, residual risks to monitor, and the data collection methods (registries, structured studies, user surveys) that will answer them, as laid out in Annex XIV Part B. Data collection follows, generating results that feed a PMCF evaluation report. That report’s findings then loop back into the CER and risk management file, updating the benefit-risk determination and, where warranted, the PSUR. Skipping the feedback loop, treating the evaluation report as an endpoint rather than an input, is a structural error that undermines the whole cycle.
MDR’s expectation of continuous, iterative evidence generation favors PMCF designs built for feasibility and speed over lengthy new randomized controlled trials as the sole evidence source. Structured comparative effectiveness studies and registry-based follow-up designs, including matched real-world cohorts and external control arms, can generate usable, statistically credible data on realistic timelines, particularly for chronic wound endpoints like time-to-closure and recurrence, where a de novo multi-year RCT may be neither feasible nor proportionate to the risk class. This doesn’t mean abandoning rigor; it means matching study design to the question and the timeline MDR expects.
A recurring notified body deficiency finding in wound care files is a PMCF plan that lacks any product-specific real-world utilization or comparative data, relying instead on generic literature review or legacy clinical trial data from the original CE marking submission. Notified body expectations on this point vary and evolve, so manufacturers should confirm current expectations directly with their own notified body rather than assuming last cycle’s accepted plan will pass unchanged this cycle.
What Are the Most Common Wound Care PMS Mistakes Manufacturers Make?
Three mistakes show up repeatedly across wound care PMS files:
- Static PMS files: Treating the PSUR and PMCF evaluation report as documents built once at CE marking and filed away, rather than as living outputs updated as new real-world data accumulates and as utilization patterns, the competitor landscape, or clinical practice shift underneath the product. MDR’s lifecycle framing assumes continuous evidence generation, a point reinforced in MDCG 2025-10; a PSUR that hasn’t materially changed across two reporting cycles despite new market experience signals to a notified body that the PMS system isn’t functioning as intended.
- Undersized or under-followed cohorts: Chronic wound endpoints like time-to-closure and recurrence require adequate sample size and follow-up duration to be statistically credible. A PMCF cohort too small or followed for too short a window to detect recurrence will not hold up under review, regardless of how favorable the topline numbers look.
- Missing comparative context: A PMCF report that describes a product’s real-world performance in isolation, without benchmarking against competing CAMPs/CTPs or standard-of-care alternatives, leaves notified bodies and payers without the comparative context they increasingly expect, especially where commercial claims already imply superiority.
Each of these is fixable with the same underlying discipline: building PMCF data collection as an ongoing operational process rather than a periodic compliance exercise, and grounding comparative claims in benchmarked, peer-reviewed data rather than internal trial results alone.
Building a PMCF File That Holds Up at Review
Treat EU MDR post-market surveillance as an ongoing evidence pipeline rather than a compliance checkbox that gets closed at CE marking. The manufacturers who avoid deficiency findings are the ones who keep their PMCF plan current, size their cohorts and follow-up windows to the endpoints that matter for chronic wounds, and build comparative context into every evaluation report rather than treating their own product’s performance as a story told in isolation. Structured real-world utilization and comparative effectiveness data, benchmarked against the broader competitive landscape rather than a single legacy trial, is what turns a PMCF file from adequate into defensible. Learn more about our PMCF services to see how real-world utilization and comparative effectiveness data can strengthen your next PMCF submission and notified body review.